View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
August 13, 2021

Coronavirus company news summary – FDA expands EUAs for Pfizer and Moderna vaccines to include third booster dose – Canada funds research into detection of Covid-19 jab adverse events

By Chris Lo

The US Food and Drug Administration has expanded the emergency use authorisations of Pfizer-BioNTech and Moderna Covid-19 vaccines to include an additional booster, or third dose for some immunocompromised people, particularly recipients of solid organ transplant or individuals with conditions that are considered to have an identical immunocompromise level. Some countries, including Israel and Germany, intend to or have already given a third dose to avoid the risk of further Delta variant cases, Reuters reported.

The Government of Canada has announced funding support for the Canadian Immunization Research Network (CIRN) to research the detection and response to potential adverse events after the Covid-19 vaccination. The study will be conducted across Canada and is expected to aid people who are at risk of adverse reactions to get a Covid-19 jab safely.

The US Government has shipped approximately 569,000 doses of the Pfizer Covid-19 vaccine to the Caribbean Community’s (CARICOM) 15 member countries. These doses were delivered to Antigua and Barbuda, The Bahamas, St. Kitts and Nevis, St. Vincent and the Grenadines, and Trinidad and Tobago on 12 August while Barbados will receive them today. The shipments are part of the 5.5 million doses that the US committed to donate to the 15 CARICOM member countries.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology